Transverse Myelitis Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You must be able to understand the goals and risks of the study, sign a consent form, and agree to your health information being used as required by privacy laws.
• You must be between 18 and 65 years old (inclusive) at the time you sign the consent form, and any biological sex may join.
• You must agree to use reliable contraception throughout the study and for at least 30 days after your last dose of the study treatment, and agree not to donate eggs or sperm during this time.
• You must have a confirmed diagnosis of AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) — a specific type of nervous system disease — confirmed by a blood or spinal fluid test, and have already agreed to treatment with a certain type of biologic medication (confirm with trial site).
• Your condition must have been neurologically stable for at least 30 days before your first study visit.

Who may not be able to join:

• You have a significant history of serious health conditions affecting the heart, liver, kidneys, immune system, lungs, hormones, blood, nerves, skin, mental health, or other major body systems that the doctor feels would make participation unsafe.
• You have had a stroke or similar brain event that has left you with significant disability (confirm with trial site).
• You have had an allergic reaction to the study drug or any of its ingredients.
• You have HIV, or have tested positive for HIV.
• You have an active hepatitis C infection with detectable virus in your blood (those with past hepatitis C but no detectable virus may still be eligible).
• You have an active hepatitis B infection based on specific blood test results (those with evidence of past natural infection or successful vaccination may still be eligible — confirm with trial site).
• You have had a serious, ongoing, or frequently recurring infection (such as severe pneumonia or blood infection) within the 90 days before your first study visit.
• You have a history of active tuberculosis (TB) or have tested positive for a latent (hidden/inactive) TB infection.
• You have had any active bacterial, fungal, or viral infection — including a common cold — within 28 days before your first study visit (those with a minor localised fungal infection may be able to re-apply after treatment).
• You cannot safely receive certain emergency treatments such as rituximab, IV immunoglobulin, high-dose steroids, or cyclophosphamide.
• You have previously received certain intensive treatments such as total body radiation, stem cell transplant, or specific immune-related therapies at any point in your life (confirm with trial site).
• You have had significant thoughts of suicide or self-harm in the past 12 months.
• You are unwilling or unable to follow the procedures required by the study.
• You have severe hearing or vision problems, significant language barriers, claustrophobia, or other conditions that would prevent you from completing psychological tests or MRI scans.
• The trial doctor or sponsor has any other concern that would affect your safety or the reliability of the study results.

Important: Always verify eligibility with the trial site directly before applying.